Latest Commercial Rollouts News

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.

Clarity Pharmaceuticals has secured a major manufacturing deal with Nucleus RadioPharma to produce its next-generation prostate cancer imaging agent, 64Cu-SAR-bisPSMA, ramping up supply ahead of anticipated US market entry.

Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Nexsen Limited (ASX:NXN) has completed its Stage 1 ISO 13485 audit, confirming its Quality Management System (QMS) supports clinical validation and regulatory submissions for its diagnostic products, including StrepSure®. The company is progressing toward full certification and alignment with MDSAP requirements to facilitate global market access.

Janus Electric has appointed Lynx Advisors and Spark Plus to bolster its capital strategy and investor engagement while settling longstanding disputes with Kjøller A/S. The company also ends its agreement with EVUNI, opening new partnership opportunities.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

ClearVue Technologies has achieved a key international certification for its innovative solar panels and is deepening its strategic alliance with Helios Power, setting the stage for expanded commercial deployment in the building-integrated photovoltaics market.

Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.

Temas Resources has commissioned a new metallurgical lab in Ontario to accelerate the scale-up and commercialisation of its innovative Regenerative Chloride Leach (RCL) technology, while securing initial third-party contracts to boost revenue.

Botanix Pharmaceuticals has successfully renegotiated its API supply agreement, deferring significant purchases to later years and strengthening its financial position ahead of Sofdra's market rollout.

Lumos Diagnostics has secured a pivotal US FDA CLIA waiver for its FebriDx® test, vastly expanding its market reach and triggering milestone payments that bolster its US commercial rollout.